These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly. Dunn PJ; Donald RA; Espiner EA Clin Endocrinol (Oxf); 1976 Mar; 5(2):167-74. PubMed ID: 1269163 [TBL] [Abstract][Full Text] [Related]
4. Increased peripheral venous somatostatin concentration and decreased glucagon response to arginine in patients with insulin dependent diabetes mellitus without residual B-cell function. Increased plasma SRIF in IDDM. Skare S; Dahl-Jørgensen K; Hanssen KF; Norman N Acta Endocrinol (Copenh); 1985 Aug; 109(4):517-21. PubMed ID: 2863913 [TBL] [Abstract][Full Text] [Related]
5. Plasma somatostatin is elevated in primary hypothyroidism compared with hyperthyroidism. Skare S; Hanssen KF; Norman N Acta Endocrinol (Copenh); 1986 Mar; 111(3):331-5. PubMed ID: 2870598 [TBL] [Abstract][Full Text] [Related]
6. Metabolic effects of graded glucagon infusions in man: inhibition of glucagon, insulin, and somatostatin response to arginine. Pontiroli AE; Perfetti MG; Andreotti AC; Fattor B; Monti LD; Pozza G Metabolism; 1993 Oct; 42(10):1242-8. PubMed ID: 8105365 [TBL] [Abstract][Full Text] [Related]
7. Dissociated effects of somatostatin analogs on arginine-induced insulin, glucagon and growth hormone release in acromegalic patients. Wajchenberg BL; Cesar FP; Leme CE; Borghi VC; Souza VC; Souza IT; Neto DG; Germek OA; Coy DH; Comaru-Schally AM Horm Metab Res; 1983 Oct; 15(10):471-4. PubMed ID: 6139329 [TBL] [Abstract][Full Text] [Related]
8. Plasma somatostatin and plasma glucagon in long-term IDDM without residual B-cell function. No effect of different long-term metabolic control. Skare S; Dahl-Jørgensen K; Kriz V; Hanssen KF Scand J Clin Lab Invest; 1986 Nov; 46(7):635-8. PubMed ID: 2878490 [TBL] [Abstract][Full Text] [Related]
9. Effect of the somatostatin analog D-Trp8,D-Cys14 on glucose insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics. Trovati M; Massara F; Camanni F; Molinatti GM; Lorenzati R; Pagano GF J Endocrinol Invest; 1980; 3(2):189-92. PubMed ID: 6104680 [TBL] [Abstract][Full Text] [Related]
10. The effect of somatostatin on plasma insulin and growth hormone levels in basal conditions and after glucagon in normal and acromegalic subjects. Massara F; Porzio G; Camanni F; Molinatti GM Acta Diabetol Lat; 1975; 12(3-4):219-31. PubMed ID: 1224905 [TBL] [Abstract][Full Text] [Related]
11. Growth hormone modulation of arginine-induced glucagon release: studies of isolated growth hormone deficiency and acromegaly. Seino Y; Taminato T; Goto Y; Inoue Y; Kadowaki S; Hattori M; Mori K; Kato Y; Matsukura S; Imura H Clin Endocrinol (Oxf); 1978 Dec; 9(6):563-70. PubMed ID: 747897 [TBL] [Abstract][Full Text] [Related]
12. Plasma glucagon and insulin concentrations in acromegaly. Trimble ER; Atkinson AB; Buchanan KD; Hadden DR J Clin Endocrinol Metab; 1980 Sep; 51(3):626-31. PubMed ID: 6997331 [TBL] [Abstract][Full Text] [Related]
13. Comparative effects of somatostatin-28 and somatostatin-14 on basal growth hormone release and pancreatic function in immature ducks (Anas platyrhynchos). Strosser MT; Harvey S; Foltzer C; Mialhe P Gen Comp Endocrinol; 1984 Nov; 56(2):265-70. PubMed ID: 6150878 [TBL] [Abstract][Full Text] [Related]
14. Prandial regulation of ghrelin secretion in humans: does glucagon contribute to the preprandial increase in circulating ghrelin? Soule S; Pemberton C; Hunt P; Cole D; Raudsepp S; Inder W Clin Endocrinol (Oxf); 2005 Oct; 63(4):412-7. PubMed ID: 16181233 [TBL] [Abstract][Full Text] [Related]
15. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients. Giustina G; Peracchi M; Reschini E; Panerai E; Pinto M Metabolism; 1975 Jul; 24(7):807-15. PubMed ID: 1138156 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the sensitivity of growth hormone secretion to somatostatin in vivo and in vitro in acromegaly. Kelijman M; Williams TC; Downs TR; Frohman LA J Clin Endocrinol Metab; 1988 Nov; 67(5):958-63. PubMed ID: 2903171 [TBL] [Abstract][Full Text] [Related]
17. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients. Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548 [TBL] [Abstract][Full Text] [Related]
18. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524 [TBL] [Abstract][Full Text] [Related]
19. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. Quabbe HJ; Plöckinger U J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912 [TBL] [Abstract][Full Text] [Related]
20. Effects of plasma amino acid and hormone levels on renal hemodynamics in humans. Castellino P; Giordano C; Perna A; DeFronzo RA Am J Physiol; 1988 Sep; 255(3 Pt 2):F444-9. PubMed ID: 2901229 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]